Kathryn A Skelding

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

Cells

Cancers

International journal of molecular sciences

Exploration of targeted anti-tumor therapy

University of Newcastle

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Newcastle Jan 01 2020

Australia

Associate Professor, Head of Cancer Cell Biology Group :: Biomedical Sciences and Pharmacy

University of Newcastle Jan 01 2016 - Dec 31 2019

Australia

Senior Lecturer, Head of Cancer Cell Biology Group :: Biomedical Sciences and Pharmacy

University of Newcastle Jan 01 2012 - Dec 31 2015

Australia

Lecturer, Group Leader :: School of Biomedical Sciences and Pharmacy

Publications

Lisa F Lincz, Danielle Z Theron, Daniel L Barry, Fiona E Scorgie, Jonathan Sillar, Opelo Sefhore, Anoop K Enjeti, Kathryn A Skelding
High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia. Cancers 16 (5) (2024)
Lisa F Lincz, Danielle Z Theron, Daniel L Barry, Fiona E Scorgie, Jonathan Sillar, Opelo Sefhore, Anoop K Enjeti, Kathryn A Skelding
High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia. Cancers 16 (5) (2024)
John A P Rostas, Kathryn A Skelding
Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment. Cells 12 (3) (2023)
John A P Rostas, Kathryn A Skelding
Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment. Cells 12 (3) (2023)
John A P Rostas, Kathryn A Skelding
Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment. Cells 12 (3) (2023)
John A P Rostas, Kathryn A Skelding
Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment. Cells 12 (3) (2023)
Kathryn A Skelding, Daniel L Barry, Danielle Z Theron, Lisa F Lincz
Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. International journal of molecular sciences 24 (1) (2022)
Kathryn A Skelding, Daniel L Barry, Danielle Z Theron, Lisa F Lincz
Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. International journal of molecular sciences 24 (1) (2022)
Kathryn A Skelding, Daniel L Barry, Danielle Z Theron, Lisa F Lincz
Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia. International journal of molecular sciences 24 (1) (2022)
Kathryn A Skelding, Daniel L Barry, Danielle Z Theron, Lisa F Lincz
Targeting the two-pore channel 2 in cancer progression and metastasis. Exploration of targeted anti-tumor therapy 3 (1) (2022)
Kathryn A Skelding, Lisa F Lincz
PARP Inhibitors and Haematological Malignancies-Friend or Foe? Cancers 13 (21) (2021)
Joshua S Brzozowski, Kathryn A Skelding
The Multi-Functional Calcium/Calmodulin Stimulated Protein Kinase (CaMK) Family: Emerging Targets for Anti-Cancer Therapeutic Intervention. Pharmaceuticals (Basel, Switzerland) 12 (1) (2019)

Kathryn A Skelding.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kathryn A Skelding